MA53189A1 - Composition pharmaceutique destinée au traitement de l'anémie aplasique - Google Patents

Composition pharmaceutique destinée au traitement de l'anémie aplasique

Info

Publication number
MA53189A1
MA53189A1 MA53189A MA53189A MA53189A1 MA 53189 A1 MA53189 A1 MA 53189A1 MA 53189 A MA53189 A MA 53189A MA 53189 A MA53189 A MA 53189A MA 53189 A1 MA53189 A1 MA 53189A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
week
treatment
aplastic anemia
composition intended
Prior art date
Application number
MA53189A
Other languages
English (en)
Other versions
MA53189B2 (fr
Inventor
Yukie Tsuji
Miyako KODAMA
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of MA53189A1 publication Critical patent/MA53189A1/fr
Publication of MA53189B2 publication Critical patent/MA53189B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique destinée au traitement de l'anémie aplasique, ladite composition contenant du romiplostim en tant qu'ingrédient actif. Cette composition pharmaceutique est caractérisée en ce qu'elle est administrée par voie sous-cutanée une fois par semaine ; et en ce que pendant les quatre premières semaines suivant le début de l'administration, la quantité administrée de romiplostim est de 10 µg/kg/semaine, puis à partir de la cinquième semaine, la quantité de romiplostim est augmentée au-delà de 10 µg/kg/semaine, jusqu'à 20 µg/kg/semaine.
MA53189A 2018-10-26 2019-10-25 Composition pharmaceutique destinée au traitement de l'anémie aplasique MA53189B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018202097 2018-10-26
PCT/JP2019/041814 WO2020085467A1 (fr) 2018-10-26 2019-10-25 Composition pharmaceutique destinée au traitement de l'anémie aplasique

Publications (2)

Publication Number Publication Date
MA53189A1 true MA53189A1 (fr) 2021-12-31
MA53189B2 MA53189B2 (fr) 2023-09-27

Family

ID=70332110

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53189A MA53189B2 (fr) 2018-10-26 2019-10-25 Composition pharmaceutique destinée au traitement de l'anémie aplasique

Country Status (16)

Country Link
US (1) US20210379154A1 (fr)
EP (1) EP3881856B1 (fr)
JP (2) JPWO2020085467A1 (fr)
KR (1) KR20210087045A (fr)
CN (1) CN112888453A (fr)
AU (1) AU2019364063A1 (fr)
BR (1) BR112021007710A2 (fr)
CA (1) CA3117477A1 (fr)
EA (1) EA202191130A1 (fr)
IL (1) IL282470A (fr)
MA (1) MA53189B2 (fr)
MX (1) MX2021004551A (fr)
SG (1) SG11202104199WA (fr)
TW (1) TW202021611A (fr)
WO (1) WO2020085467A1 (fr)
ZA (1) ZA202102940B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114027263A (zh) * 2021-12-01 2022-02-11 上海中医药大学 一种获得性再生障碍性贫血模型小鼠的生产方法
WO2023149443A1 (fr) * 2022-02-02 2023-08-10 国立大学法人 筑波大学 Composition pharmaceutique pour la récupération des cellules sanguines après une greffe de sang de cordon
WO2024028744A1 (fr) * 2022-08-01 2024-02-08 Zydus Lifesciences Limited Traitement de l'anémie aplasique (aa)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773891C (en) * 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
WO2002015926A1 (fr) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes
JP6559185B2 (ja) 2017-06-09 2019-08-14 株式会社カプコン ゲームプログラムおよびゲーム装置

Also Published As

Publication number Publication date
AU2019364063A1 (en) 2021-06-10
IL282470A (en) 2021-06-30
EP3881856B1 (fr) 2024-08-07
US20210379154A1 (en) 2021-12-09
SG11202104199WA (en) 2021-05-28
MA53189B2 (fr) 2023-09-27
WO2020085467A1 (fr) 2020-04-30
CN112888453A (zh) 2021-06-01
BR112021007710A2 (pt) 2021-08-10
KR20210087045A (ko) 2021-07-09
TW202021611A (zh) 2020-06-16
EP3881856A1 (fr) 2021-09-22
JP2024123116A (ja) 2024-09-10
JPWO2020085467A1 (ja) 2021-09-16
ZA202102940B (en) 2022-10-26
EA202191130A1 (ru) 2021-07-22
EP3881856A4 (fr) 2022-06-29
CA3117477A1 (fr) 2020-04-30
MX2021004551A (es) 2021-07-16

Similar Documents

Publication Publication Date Title
MA53189A1 (fr) Composition pharmaceutique destinée au traitement de l'anémie aplasique
MA44206A (fr) Comprimé orodispersible comprenant estetrol
US20160136231A1 (en) Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
MD3548091T2 (ro) Prepararea complexelor solide de ciclodextrină pentru livrarea ingredientelor farmaceutice active oftalmice
AU2014261009A1 (en) Compositions of pharmaceutical actives containing Diethylene glycol monoethyl ether or other alkyl derivatives
MA44205A (fr) Comprimé orodispersible comprenant estetrol
WO2013065028A1 (fr) Combinaison de dose fixe contenant de l'azithromycine et du lotéprednol pour le traitement d'infections oculaires
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
EA202190115A1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения
JP2019507786A5 (fr)
TWI250023B (en) Pharmaceutical composition for itch treating agent
MX2022006502A (es) Composiciones farmaceuticas.
MA45202B1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
JP6509244B2 (ja) 水晶体硬化抑制剤
FR3059236B1 (fr) Extraits de plantes du genre tagetes et leurs utilisations
MA58507A1 (fr) Composition pharmaceutique aqueuse de levilimab
MA53521B1 (fr) Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications
MX2023001572A (es) Formas farmaceuticas sólidas de palbociclib.
MA61742A1 (fr) Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation
DE60306133T2 (de) Verbindung eines antithrombotischen mittels mit aspirin und dessen verwendung zur behandlung von atherothrombotischen erkrankungen
MA43793B1 (fr) Procédé de préparation de formulations solides de mésalazine
JP5272384B2 (ja) 口腔粘膜疾患の治療剤
JP2001163772A (ja) 抗白内障剤
MA39952A (fr) Programme de traitement pour composé de tiacumicin
MA60150A1 (fr) Procédés de réduction du risque d'événements cardiovasculaires chez un sujet